DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Wegovy is FDA-approved to reduce major adverse cardiovascular events in adults with established cardiovascular disease and BMI ≥ 27, with or without diabetes. It is the strongest insurance pathway in the category and the only realistic Medicare route in 2026.
The SELECT trial (NEJM 2023, Lincoff et al.) enrolled 17,604 adults with established cardiovascular disease and BMI ≥ 27 without diabetes. Weekly semaglutide 2.4 mg reduced the primary 3-point MACE composite (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) by 20% (HR 0.80, 95% CI 0.72–0.90) over a mean ~40 months. In type 2 diabetes, SUSTAIN-6 (NEJM 2016) showed a 26% MACE reduction with semaglutide 0.5/1.0 mg. The cardiovascular benefit appears only partly explained by weight loss.
Cardiology co-management is common. Documented prior MI, ischemic stroke, or symptomatic peripheral arterial disease (or coronary/peripheral revascularization) plus BMI ≥ 27 unlocks the on-label cardiovascular pathway, which carries the highest prior-authorization approval rate in the category. Ozempic carries a separate MACE-reduction indication for type 2 diabetes with established CVD.
The cardiovascular indication is the cleanest 2026 PA route and the only Medicare Part D pathway for Wegovy: weight-loss-only use remains statutorily excluded by Medicare, but CV risk reduction in patients with established CVD is covered. Bill the cardiovascular ICD-10 code (e.g. I25.10), not the obesity code. Commercial approvals run high with documented qualifying events.
Adjunctive only. Does not replace statin, blood-pressure, or antiplatelet therapy in established cardiovascular disease. Standard GLP-1 cautions apply (personal/family history of medullary thyroid carcinoma or MEN 2, pancreatitis history, pregnancy).
For patients with a prior cardiovascular event and BMI ≥ 27, Wegovy is now a first-line consideration on the cardiometabolic merits, and the CV indication is the surest way to obtain coverage — including under Medicare, where the weight-loss pathway is closed.
Yes. Switching from Ozempic (semaglutide) to Mounjaro (tirzepatide) is common and clinically supported for type 2 diabetes patients seeking better A1C reduction.
Yes. Switching from Wegovy (semaglutide) to Zepbound (tirzepatide) is supported when Wegovy intolerance, plateau, or coverage loss occurs. Restart titration at Zepbound 2.5mg.
On raw weight loss, yes — Zepbound delivers ~22% body weight loss vs Wegovy ~15% in clinical trials. On cardiovascular outcomes evidence, Wegovy is ahead.
Most GI side effects (nausea, constipation, sulfur burps) resolve within 4-8 weeks as your body adjusts. Side effects flare again with each dose escalation.
Side effect profiles are similar. Zepbound users report slightly more fatigue at higher doses (10mg+). Wegovy users report more sulfur burps. Discontinuation rates ~comparable.
Yes, in moderation. Alcohol on Wegovy is not contraindicated, but most patients report dramatically reduced tolerance — 1-2 drinks may feel like 3-4.
Editorial summary, not medical advice. Off-label and emerging uses should be discussed with a qualified clinician. Trial outcomes do not predict individual results.